
Zealand Pharma A/S
CSE:ZEAL

Intrinsic Value
The intrinsic value of one
ZEAL
stock under the Base Case scenario is
141.18
DKK.
Compared to the current market price of 353.5 DKK,
Zealand Pharma A/S
is
Overvalued by 60%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Zealand Pharma A/S
Fundamental Analysis


Revenue & Expenses Breakdown
Zealand Pharma A/S
Balance Sheet Decomposition
Zealand Pharma A/S
Current Assets | 9B |
Cash & Short-Term Investments | 8.5B |
Receivables | 159.9m |
Other Current Assets | 253.7m |
Non-Current Assets | 164.1m |
PP&E | 129.6m |
Intangibles | 14.1m |
Other Non-Current Assets | 20.4m |
Free Cash Flow Analysis
Zealand Pharma A/S
DKK | |
Free Cash Flow | DKK |
Earnings Waterfall
Zealand Pharma A/S
Revenue
|
55.7m
DKK
|
Cost of Revenue
|
-3.7m
DKK
|
Gross Profit
|
52m
DKK
|
Operating Expenses
|
-1.5B
DKK
|
Operating Income
|
-1.4B
DKK
|
Other Expenses
|
216.3m
DKK
|
Net Income
|
-1.2B
DKK
|
ZEAL Profitability Score
Profitability Due Diligence
Zealand Pharma A/S's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Score
Zealand Pharma A/S's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
ZEAL Solvency Score
Solvency Due Diligence
Zealand Pharma A/S's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Score
Zealand Pharma A/S's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZEAL Price Targets Summary
Zealand Pharma A/S
According to Wall Street analysts, the average 1-year price target for
ZEAL
is 927.44 DKK
with a low forecast of 489.85 DKK and a high forecast of 1 176 DKK.
Dividends
Current shareholder yield for ZEAL is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ZEAL
stock under the Base Case scenario is
141.18
DKK.
Compared to the current market price of 353.5 DKK,
Zealand Pharma A/S
is
Overvalued by 60%.